Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies (original) (raw)
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Alan Kivitz
The Journal of Rheumatology, 2014
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Erika García, Karina Santana, Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies
Erika García, Karina Santana, Daniel Xavier Xibille Friedmann
Reumatología Clínica, 2017
View PDFchevron_right
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Nandini Kishore
Journal of Pharmacology and Experimental Therapeutics, 2013
View PDFchevron_right
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Cristiano Moura
Arthritis research & therapy, 2018
View PDFchevron_right
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Andrzej Pilc
Clinical Rheumatology, 2013
View PDFchevron_right
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Irmgadt Sariego
Lancet (London, England), 2017
View PDFchevron_right
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
Jonathan French
Arthritis & Rheumatism, 2012
View PDFchevron_right
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
Joel Kremer
2019
View PDFchevron_right
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Joel Kremer
New England Journal of Medicine, 2012
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Jamie Geier
Annals of the rheumatic diseases, 2015
View PDFchevron_right
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial
vibeke strand
Arthritis Care & Research, 2016
View PDFchevron_right
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Jamie Geier
Annals of the rheumatic diseases, 2017
View PDFchevron_right
Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
Kay Myint, Soe Moe
ISRN Rheumatology, 2013
View PDFchevron_right
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study
Shrikant Wagh
Arthritis & Rheumatology, 2019
View PDFchevron_right
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical
Yoshiya Tanaka
Modern Rheumatology, 2013
View PDFchevron_right
Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
vibeke strand
Arthritis care & research, 2015
View PDFchevron_right
Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3 Trial
vibeke strand
View PDFchevron_right
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
Joel Kremer
Arthritis Care & Research, 2017
View PDFchevron_right
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
vibeke strand
Arthritis Research & Therapy, 2015
View PDFchevron_right
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Mark Genovese
Arthritis research & therapy, 2016
View PDFchevron_right
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Maria Kózka
Therapeutics and clinical risk management, 2018
View PDFchevron_right
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
Mark Genovese
Annals of Internal Medicine, 2013
View PDFchevron_right
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
Shahin Jamal
ACR Open Rheumatology, 2019
View PDFchevron_right
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Alan Worsley, Ying He
BMC Musculoskeletal Disorders, 2013
View PDFchevron_right
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
vibeke strand
Rheumatology and therapy, 2018
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies
Juan Jaller
Revista Colombiana de Reumatología, 2018
View PDFchevron_right
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study
Yoshiya Tanaka
Rheumatology (Oxford, England), 2018
View PDFchevron_right